Suzanne M M Verstappen1, Johan Askling2, Niklas Berglind3, Stefan Franzen3, Thomas Frisell4, Christopher Garwood1, Jeffrey D Greenberg5, Marie Holmqvist4, Laura Horne6, Kathy Lampl6, Kaleb Michaud7, Fredrik Nyberg8, Dimitrios A Pappas9, George Reed10, Deborah P M Symmons11, Eiichi Tanaka12, Trung N Tran13, Hisashi Yamanaka12, Meilien Ho14. 1. University of Manchester, Manchester, UK. 2. Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden. 3. AstraZeneca, MöIndal, Sweden. 4. Karolinska Institutet, Stockholm, Sweden. 5. New York University School of Medicine, New York, and CORRONA, Southborough, Massachusetts. 6. AstraZeneca, Wilmington, Delaware. 7. University of Nebraska Medical Center, Omaha, and the National Data Bank for Rheumatic Diseases, Wichita, Kansas. 8. AstraZeneca, MöIndal, Sweden, and University of Gothenburg, Gothenburg, Sweden. 9. Columbia University College of Physicians and Surgeons, New York, New York. 10. University of Massachusetts Medical School, Worcester. 11. Manchester Academic Health Science Centre, Central Manchester NHS Foundation Trust, and University of Manchester, Manchester, UK. 12. Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan. 13. MedImmune, Gaithersburg, Maryland. 14. AstraZeneca, Macclesfield, UK.
Abstract
OBJECTIVE: Comparisons of data from different registries can be helpful in understanding variations in many aspects of rheumatoid arthritis (RA). The study aim was to assess and improve the comparability of demographic, clinical, and comorbidity data from 5 international RA registries. METHODS: Using predefined definitions, 2 subsets of patients (main cohort and subcohort) from 5 international observational registries (Consortium of Rheumatology Researchers of North America Registry [CORRONA], the Swedish Rheumatology Quality of Care Register [SRR], the Norfolk Arthritis Register [NOAR], the Institute of Rheumatology Rheumatoid Arthritis cohort [IORRA], and CORRONA International) were evaluated and compared. Patients ages >18 years with RA, and present in or recruited to the registry from January 1, 2000, were included in the main cohort. Patients from the main cohort with positive rheumatoid factor and/or erosive RA who had received ≥1 synthetic disease-modifying antirheumatic drug (DMARD), and switched to or added another DMARD, were included in the subcohort at time of treatment switch. RESULTS: Age and sex distributions were fairly similar across the registries. The percentage of patients with a high Disease Activity Score in 28 joints score varied between main cohorts (17.5% IORRA, 18.9% CORRONA, 24.7% NOAR, 27.7% CORRONA International, and 36.8% SRR), with IORRA, CORRONA, and CORRONA International including more prevalent cases of RA; the differences were smaller for the subcohort. Prevalence of comorbidities varied across registries (e.g., coronary artery disease ranged from 1.5% in IORRA to 7.9% in SRR), partly due to the way comorbidity data were captured and general cultural differences; the pattern was similar for the subcohorts. CONCLUSION: Despite different inclusion criteria for the individual RA registries, it is possible to improve the comparability and interpretability of differences across RA registries by applying well-defined cohort definitions.
OBJECTIVE: Comparisons of data from different registries can be helpful in understanding variations in many aspects of rheumatoid arthritis (RA). The study aim was to assess and improve the comparability of demographic, clinical, and comorbidity data from 5 international RA registries. METHODS: Using predefined definitions, 2 subsets of patients (main cohort and subcohort) from 5 international observational registries (Consortium of Rheumatology Researchers of North America Registry [CORRONA], the Swedish Rheumatology Quality of Care Register [SRR], the Norfolk Arthritis Register [NOAR], the Institute of Rheumatology Rheumatoid Arthritis cohort [IORRA], and CORRONA International) were evaluated and compared. Patients ages >18 years with RA, and present in or recruited to the registry from January 1, 2000, were included in the main cohort. Patients from the main cohort with positive rheumatoid factor and/or erosive RA who had received ≥1 synthetic disease-modifying antirheumatic drug (DMARD), and switched to or added another DMARD, were included in the subcohort at time of treatment switch. RESULTS: Age and sex distributions were fairly similar across the registries. The percentage of patients with a high Disease Activity Score in 28 joints score varied between main cohorts (17.5% IORRA, 18.9% CORRONA, 24.7% NOAR, 27.7% CORRONA International, and 36.8% SRR), with IORRA, CORRONA, and CORRONA International including more prevalent cases of RA; the differences were smaller for the subcohort. Prevalence of comorbidities varied across registries (e.g., coronary artery disease ranged from 1.5% in IORRA to 7.9% in SRR), partly due to the way comorbidity data were captured and general cultural differences; the pattern was similar for the subcohorts. CONCLUSION: Despite different inclusion criteria for the individual RA registries, it is possible to improve the comparability and interpretability of differences across RA registries by applying well-defined cohort definitions.
Authors: David Nickerson; Koray Atalag; Bernard de Bono; Jörg Geiger; Carole Goble; Susanne Hollmann; Joachim Lonien; Wolfgang Müller; Babette Regierer; Natalie J Stanford; Martin Golebiewski; Peter Hunter Journal: Interface Focus Date: 2016-04-06 Impact factor: 3.906
Authors: Hisashi Yamanaka; Johan Askling; Niklas Berglind; Stefan Franzen; Thomas Frisell; Christopher Garwood; Jeffrey D Greenberg; Meilien Ho; Marie Holmqvist; Laura Novelli Horne; Eisuke Inoue; Kaleb Michaud; Dimitrios A Pappas; George Reed; Deborah Symmons; Eiichi Tanaka; Trung N Tran; Suzanne M M Verstappen; Eveline Wesby-van Swaay; Fredrik Nyberg Journal: RMD Open Date: 2017-10-10
Authors: Sarah Twigg; Elena Nikiphorou; Jackie L Nam; Laura Hunt; Kulveer Mankia; Peta Elizabeth Pentony; Jane E Freeston; Ai Lyn Tan; Paul Emery Journal: Front Med (Lausanne) Date: 2018-02-19